4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
November 18, 2024 08:00 ET
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and...
4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
November 18, 2024 02:00 ET
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and...
4BIO Capital Becomes First UK Venture Fund Certified by Japan's AMED
November 14, 2024 08:00 ET
|
4Bio Capital
Press Release 4BIO Capital Becomes First UK Venture Fund Certified by Japan's AMED 4BIO Capital named as the first and only UK-based venture fund to be accredited by the Japan Agency for Medical...
4BIO Capital Becomes First UK Venture Fund Certified by Japan's AMED
November 14, 2024 03:00 ET
|
4Bio Capital
Press Release 4BIO Capital Becomes First UK Venture Fund Certified by Japan's AMED 4BIO Capital named as the first and only UK-based venture fund to be accredited by the Japan Agency for Medical...
4BIO Capital Strengthens Investment Team
November 04, 2024 08:00 ET
|
4Bio Capital
Press Release LONDON, 4 November 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced and emerging therapies sector, announces today the...
4BIO Capital Strengthens Investment Team
November 04, 2024 03:00 ET
|
4Bio Capital
Press Release LONDON, 4 November 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced and emerging therapies sector, announces today the...
4BIO Capital leads oversubscribed $28.4 million Series A financing of March Biosciences
October 23, 2024 08:05 ET
|
4Bio Capital
March Bio is rapidly advancing its innovative autologous chimeric antigen receptor T-cell (CAR-T) therapy, MB-105, in development for the treatment of relapsed and refractory CD5 positive T-cell...
Biopharmaceutical Market to Reach USD 1,829.2 Billion by 2033, Growing at 15.4% CAGR | Dimension Market Research
June 10, 2024 10:12 ET
|
Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Overview: The Global Biopharmaceutical Market size reached USD 436.7 billion in 2023 and is further anticipated to reach USD 1,829.2 billion by 2033...
Chronic Wound Care Market is expected to see an expansion to US$16.7 billion, as per the projections, By the end of 2030 | Persistence Market Research
January 22, 2024 01:15 ET
|
Persistence Market Research
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Chronic Wound Care Market Booms as Advanced Solutions Emerge to Combat Rising Burden Chronic wound care involves the management and treatment of wounds...
Single Use Support continues to grow, expanding its team by 40%
January 16, 2024 07:45 ET
|
Single Use Support
The forecast for innovative process solution provider Single Use Support promises growth, exemplified by the addition of 40% more staff members.